Dongin (Donoven) Kim, Ph.D.
Assistant Professor
Pharmaceutical Sciences
Phone (405) 271-6593 x 47473
Office College of Pharmacy, CPB 317
Email dongin-kim@ouhsc.edu
Publications & Presentations
- 11. Rana S, Kang C, Allred J, Medina-Duran J H, Canova A, Sherry D, Woller D A, Kim D, Song H. Differential responses to double-stranded RNA injection and feeding in Mormon cricket (Orthoptera: Tettigoniidae) . Journal of Insect Science/Oxford Academic. 2023; 23
12. Ren X, Kang C, Garcia-Contreras L, Kim D. Understanding of Ovarian Cancer Cell-Derived Exosome Tropism for Future Therapeutic Applications. International Journal of Molecular Sciences/MDPI. 2023; 24 : 8166
13. Kang C, Ren X, Garcia-Contreras L, Kim D. Understanding of Ovarian Cancer Cell-Derived Exosome Tropism for Future Therapeutic Applications. International Journal of Molecular Sciences . 2023; 24 : 8166
14. Kim D. A Kidney-Targeted Nanoparticle to Augment Renal Lymphatic Density Decreases Blood Pressure in Hypertensive Mice. Pharmaceutics/MDPI. 2022; 14 : 84
15. Kim D. Intraocular RGD-Engineered exosomes and active targeting of choroidal neovascularization (CNV). Cells/MDPI. 2022; 11 : 2573
Grants
- 1. Extracellular Vesicle-Based Intraocular Therapy Combined with Active Targeting of Ocular Neovascularization. NEI. Start Date: 2024. End Date: 2029.
2. MiPEP133, a New Tumor Suppressor for Ovarian Cancer. American Cancer Society. Start Date: 2024. End Date: 2027.
3. Extracellular Vesicle Therapy for Diabetic Retinopathy. NEI. Start Date: 2023. End Date: 2024.
4. Lymphatics and lymphangiogenesis in kidney function and inflammation. NIH. Start Date: 2019. End Date: 2024.
5. Extracellular Vesicle Therapy for Diabetic Retinopathy. NEI. Start Date: 2023. End Date: 2024.
Awards and Honors
no results
Education
- 1. Degree: Ph D. University of Utah. Date: 2009.
2. Degree: MS. University of Florida. Date: 2002.
3. Degree: BS. Ajou University. Date: 1999.
Administrative Assignments
no results